Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Receivables (2016 - 2025)

Traws Pharma's Receivables history spans 12 years, with the latest figure at $3.8 million for Q4 2025.

  • Quarterly results put Receivables at $3.8 million for Q4 2025, up 114.96% from a year ago — trailing twelve months through Dec 2025 was $3.8 million (up 114.96% YoY), and the annual figure for FY2025 was $3.8 million, up 114.96%.
  • Receivables for Q4 2025 was $3.8 million at Traws Pharma, up from $2.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $3.8 million in Q4 2025 to a low of $17000.0 in Q1 2023.
  • The 5-year median for Receivables is $28000.0 (2021), against an average of $649400.0.
  • The sharpest move saw Receivables tumbled 39.29% in 2023, then surged 11683.33% in 2024.
  • Year by year, Receivables stood at $28000.0 in 2021, then increased by 3.57% to $29000.0 in 2022, then tumbled by 37.93% to $18000.0 in 2023, then skyrocketed by 9705.56% to $1.8 million in 2024, then surged by 114.96% to $3.8 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $3.8 million, $2.0 million, and $1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.